Cryolife Inc (CRY) is Initiated by Lake Street to Buy, Price Target at $15

Cryolife Inc (CRY) was Initiated by Lake Street to “Buy” and the brokerage firm has set the Price Target at $15. Lake Street advised their investors in a research report released on Jun 15, 2016.

Many Wall Street Analysts have commented on Cryolife Inc. Cryolife Inc was Downgraded by Ladenburg Thalmann to ” Neutral” on Apr 28, 2016. Cryolife Inc was Resumed by Piper Jaffray to “Overweight” on Apr 21, 2016. Canaccord Genuity Initiated Cryolife Inc on Apr 13, 2016 to “Buy”, Price Target of the shares are set at $14.

On the company’s financial health, Cryolife Inc reported $0.10 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Apr 27, 2016. Analyst had a consensus of $0.04. The company had revenue of $43.00 million for the quarter, compared to analysts expectations of $41.32 million. The company’s revenue was up 27.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.01 EPS.

Cryolife Inc opened for trading at $11.93 and hit $12.09 on the upside on Tuesday, eventually ending the session at $12.05, with a gain of 0.50% or 0.06 points. The heightened volatility saw the trading volume jump to 1,10,311 shares. Company has a market cap of $393 M.

In a different news, on Jun 3, 2016, Ronald D Mccall (director) sold 10,000 shares at $11.56 per share price. According to the SEC, on May 12, 2016, James Benson (director) sold 5,000 shares at $12.22 per share price. On Apr 19, 2016, C Elkins Ronald (director) sold 1,000 shares at $12.00 per share price, according to the Form-4 filing with the securities and exchange commission.

CryoLife Inc. (CryoLife) is a medical device company. The Company is engaged in medical device manufacturing and distribution and in the processing and distribution of implantable human tissues for cardiac and vascular surgeries. The Company operates in two segments: Medical Devices and Preservation Services. The Medical Devices segment includes external revenues from product sales of BioGlue BioFoam PerClot CardioGenesis cardiac laser therapy HeRO Graft and ProCol. The Preservation Services segment includes external services revenues from the preservation of cardiac and vascular tissues. The Company’s product BioGlue is a polymer consisting of bovine blood protein and an agent for cross-linking proteins which was developed for use in cardiac vascular pulmonary and surgical applications. The Company developed BioFoam to seal organs such as the liver and for use in cardiovascular surgeries and provide hemostasis in penetrating wounds and trauma.

Cryolife Inc

Leave a Reply

Cryolife Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Cryolife Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.